Publication
Skoulidis F, Ahn MJ, Gadgeel S, et al. Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC (Krascendo 1). N Engl J Med, 2026
PMID 42929675
Open-label phase 3 RCT (Roche), 338 patients with previously treated KRAS G12C-mutated advanced NSCLC. Divarasib vs sotorasib/adagrasib: median PFS 9.8 vs 5.7 months (HR 0.58; 95% CI 0.44-0.76); median OS 17.7 vs 12.0 months (HR 0.56; 95% CI 0.41-0.78); grade 3-4 treatment-related AEs 24.6% vs 34.5%.
Also in the catalogue
- Liu J, Yi T, Xing P, et al. Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion (MILD-MT). N Engl J Med, 2026Publication
- Insulin icodecDrug
- Zolacabtagene autoleucelDrug
- DivarasibDrug
- Sgouropoulou D, et al. Midlife physical activity trajectories are associated with reduced physical pre-frailty/frailty in older age: ATTICA 2002-2024. J Frailty Aging, 2026Publication
- Kanazawa H, et al. Additive effects of active vitamin D3 or vitamin E administration on therapeutic lower-limb home exercise for knee osteoarthritis: a pilot prospective randomized controlled trial. Medicine (Baltimore), 2026Publication
Scales
Identifiers
- PMID
- 42929675
- DOI
- 10.1056/NEJMoa2605703
Original sources
Details
- Journal
- N Engl J Med
- Year
- 2026
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.